Loading…
Proceeds to fund cancer immunotherapy development.
CEL-SCI announced CEL-SCI Announces $5.7M Best-Efforts Offering Of 1.5M Shares At $3.82/Share; To Fund Cancer Immunotherapy Development.
The announcement cited $5.7M, 1.5M shares, and $3.82/share. Share consideration (payable in the issuer's shares): 1,500,000.
Cel-Sci Corporation has a free float of 6,317,800 shares and 7,993,400 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.